- Home
- AMRN vs CADL Comparison
AMRN vs CADL Comparison
Compare AMRN & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$14.74
HOLD
Current Price
$5.68
Company Overview
Basic Information| Metric | AMRN | CADL |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 320.6M |
| IPO Year | 1993 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMRN | CADL |
|---|---|---|
| Price | $14.74 | $5.68 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $12.00 | ★ $19.43 |
| AVG Volume (30 Days) | 80.3K | ★ 667.2K |
| Earning Date | 02-25-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $226,733,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $4.25 |
| 52 Week High | $20.90 | $13.68 |
Technical Indicators
Market Signals| Indicator | AMRN | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 46.79 |
| Support Level | $14.38 | $5.40 |
| Resistance Level | $15.33 | $5.91 |
| Average True Range (ATR) | 0.74 | 0.34 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 55.64 | 41.76 |
Price Performance
Historical Comparison AMRN
CADL
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.